Urinary prostate cancer antigen 3 as a tumour marker: Biochemical and clinical aspects

Advances in Experimental Medicine and Biology

Volumn 867, Issue , 2015, Pages 277-289

  Schmid, Marianne ^a   Hansen, Jens ^a   Chun, Felix K H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

5 a reductase inhibitor; AMACR; Circulating tumour cells; Diagnosis; Gene therapy; Gleason score; GOLM1; PCA3; PCA3 nomogram; Performance characteristics; Prostate biopsy; Prostate cancer; Prostate cancer antigen 3 score; PSA; SPINK1; Transmembrane serine protease; Urine analysis

Indexed keywords

DUTASTERIDE; MESSENGER RNA; PLACEBO; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TMPRSS2 ERG FUSION PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ADVANCED CANCER; CANCER GENE THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CIRCULATING TUMOR CELL; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; DISEASE SURVEILLANCE; HUMAN; PATIENT COUNSELING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME; URINALYSIS; BIOPSY; EARLY DIAGNOSIS; MALE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS; TUMOR EMBOLISM; URINE;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84946713212     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-94-017-7215-0_17     Document Type: Chapter

References (62)

1. National Cancer Institute (2013) Prostate cancer 2013. http://www.cancer.gov/types/prostate. Accessed 27 Mar 2013
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29
3. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH et al (2002) Overdiagnosis due to prostate-specifi c antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981–990
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al (2009) Screening and prostatecancer mortality in a randomized European study. N Engl J Med 360:1320–1328
5. Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64:10–19
6. Huber PR, Schnell Y, Hering F, Rutishauser G (1987) Prostate specifi c antigen. Experimental and clinical observations. Scand J Urol Nephrol Suppl 104:33–39
7. Madu CO, Lu Y (2010) Novel diagnostic biomarkers for prostate cancer. J Cancer 1:150–177
8. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA et al (1999) DD3: a new prostate-specifi c gene, highly overexpressed in prostate cancer. Cancer Res 59:5975–5979
9. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C et al (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52:1089–1095
10. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF et al (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54:1081–1088
11. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM et al (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532–535
12. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI et al (2010) Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 183: 534–538
13. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW et al (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587–1592
14. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF et al (2009) Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 56:659–667
15. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV et al (2008) PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179:1804–1809; discussion 9–10
16. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B et al (2008) PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180:1975–1978; discussion 8–9
17. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW et al (2010) Predictive value of PCA3 in urinary sediments in determining clinicopathological characteristics of prostate cancer. Prostate 70:10–16
18. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H et al (2011) Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59:96–105
19. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ et al (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specifi c antigen in prescreened men: exploring the value of PCA3 for a fi rst-line diagnostic test. Eur Urol 58:475–481
20. ® PCA3 assay
21. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A et al (2011) Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 60:1045–1054
22. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ et al (2005) Operating characteristics of prostate-specifi c antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294:66–70
23. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A (2011) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 50(Suppl 1):61–75
24. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
25. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW et al (2002) DD3(PCA3), a very sensitive and specifi c marker to detect prostate tumors. Cancer Res 62:2695–2698
26. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B et al (2003) DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8–15; discussion 15−6
27. Tinzl M, Marberger M, Horvath S, Chypre C (2004) DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. Eur Urol 46:182–186; discussion 7
28. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C et al (2004) uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64:311–315; discussion 5–6
29. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL et al (2008) A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clinica Chim Acta; Int J Clin Chem 389:1–6
30. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ (2009) PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 73:363–368
31. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT (2009) Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 115:3879–3886
32. Nyberg M, Ulmert D, Lindgren A, Lindstrom U, Abrahamsson PA, Bjartell A (2010) PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population. Scand J Urol Nephrol 44:378–383
33. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H et al (2010) PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184: 1947–1952
34. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319
35. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P et al (2011) Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 185:2119–2125
36. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF et al (2010) The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specifi c antigen ratio infl uence the performance of the PCA3 score in predicting positive biopsies? BJU Int 106:1143–1147
37. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH et al (2008) Predicting prostate cancer risk through incorporation of prostate cancer gene J Urol 180:1303–1308; discussion 8
38. Kattan MW (2003) Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95:634–635
39. Kattan MW (2004) Evaluating a new marker’s predictive contribution. Clin Cancer Res 10:822–824
40. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M et al (2010) External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58:727–732
41. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M et al (2013) Initial prostate biopsy: development and internal validation of a biopsy-specifi c nomogram based on the prostate cancer antigen 3 assay. Eur Urol 63:201–209
42. Perdona S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P et al (2011) Prostate cancer detection in the “grey area” of prostate-specifi c antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, two risk estimators incorporating prostate cancer antigen. Eur Urol 59:81–87
43. Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG (2007) Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 69:215–220
44. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical fi ndings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368–374
45. Bostwick DG, Gould VE, Qian J, Susani M, Marberger M (2006) Prostate cancer detected by uPM3: radical prostatectomy fi ndings. Mod Pathol 19:630–633
46. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF et al (2008) Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68:1215–1222
47. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A et al (2011) Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 59:422–429
48. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64
49. Larre S, Ronsin C, Irani J (2010) Immediate impact of ultrasound-guided prostate biopsies on PCA3 score. Eur Urol 57:1121–1122
50. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA (2009) Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallelgroup pilot study. Prostate 69:1624–1634
51. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA (2007) Detection of TMPRSS2- ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13:5103–5108
52. Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R et al (2008) A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68:645–649
53. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM (2009) A duplex quantitative polymerase chain reaction assay based on quantifi cation of alpha-methylacyl- CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 181:2508–2513; discussion 13–4
54. Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A et al (2010) PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 70:1760–1767
55. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E et al (2007) Circulating tumor cell number and prognosis in progressive castrationresistant prostate cancer. Clin Cancer Res 13:7053–7058
56. Vaananen RM, Rissanen M, Kauko O, Junnila S, Vaisanen V, Nurmi J et al (2008) Quantitative realtime RT-PCR assay for PCA3. Clin Biochem 41:103–108
57. Marangoni K, Araujo TG, Neves AF, Goulart LR (2008) The -786 T > C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression. BMC Cancer 8:273
58. Shaw G, Price AM, Ktori E, Bisson I, Purkis PE, McFaul S et al (2008) Hedgehog signalling in androgen independent prostate cancer. Eur Urol 54:1333–1343
59. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M et al (2010) Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer 9:174
60. van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, Schalken JA et al (2001) A novel method for the determination of basal gene expression of tissue-specifi c promoters: an analysis of prostate-specifi c promoters. Cancer Gene Ther 8:927–935
61. Fan JK, Wei N, Ding M, Gu JF, Liu XR, Li BH et al (2010) Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin- 24 gene. Int J Cancer 127:707–717
62. Hessels D, Schalken JA (2009) The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 6: 255–261